Vincent Funari, PhD

Chief Science Officer, Imagia Canexia Health

Vincent Funari Ph.D. joined Imagia Canexia Health as the newly appointed Chief Science Officer (CSO) in 2022. Most recently Vincent was Chief Science Officer of NeoGenomics and will apply his two-decades worth of unique proficiency—leading the intersection of genomics and bioinformatics particularly artificial intelligence—to deliver precision cancer treatments for patients in large centralized oncology platforms.

Throughout his career, he co-authored more than 45 peer-reviewed genomics papers in publications including: Nature Immunology, JAMA, Science, Nature Genetics, AJHG, and Genomics. Vincent joins ICH to realize their vision to combine advanced genomics, oncology, artificial intelligence, and informatics so health systems can provide cost-effective cancer testing in-house.

Vincent spent his entire career leveraging technology to create the biggest changes in precision medicine to improve patient care, and cancer remains one of the biggest battle grounds of our time. Leading ICH’s scientific efforts to provide treatment-testing for more people is incredibly motivating and humbling, but clearly the next battle in the war against cancer.